{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:15:16Z","timestamp":1791292516557,"version":"4.1.0"},"reference-count":66,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T00:00:00Z","timestamp":1495411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of KwaZulu-Natal College of Health Sciences Doctoral Research Scholarship Grant"},{"name":"Health and Welfare Sector Education and Training Authority (HWSETA)"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0177762","type":"journal-article","created":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T17:39:36Z","timestamp":1495474776000},"page":"e0177762","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":20,"title":["Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0993-8308","authenticated-orcid":true,"given":"Themba G.","family":"Ginindza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benn","family":"Sartorius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xolisile","family":"Dlamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellinor","family":"\u00d6stensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,5,22]]},"reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2165\/11594780-000000000-00000","article-title":"Evaluating the epidemiology and morbidity burden associated with human papillomavirus in Israel: accounting for CIN1 and genital warts in addition to CIN2\/3 and cervical cancer","volume":"10","author":"O Shavit","year":"2012","journal-title":"Appl Health Econ Health Policy"},{"issue":"4 Suppl 2","key":"ref2","first-page":"S2","article-title":"Reducing the economic burden of HPV-related diseases","volume":"108","author":"EJ Mayeaux Jr","year":"2008","journal-title":"J Am Osteopath Assoc"},{"key":"ref3","article-title":"Current cervical cancer prevention strategies including cervical screening and prophylactic human papillomavirus vaccination: a review","author":"KM Elfstrom","year":"2013","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.18553\/jmcp.2010.16.3.217","article-title":"Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types","volume":"16","author":"EP Armstrong","year":"2010","journal-title":"J Manag Care Pharm"},{"key":"ref5","unstructured":"Merck &amp; Co. Highlights of prescribing information. Gardasil (human papillomavirus quadrivalent [types 6, 11, 16, and 18] vaccine, recombinant] suspension for intramuscular injection Revised October 2009."},{"key":"ref6","unstructured":"GlaxoSmithKline. Highlights of prescribing information. Cervarix (human papillomavirus bivalent [types 16 and 18] vaccine, recombinant]) suspension for intramuscular injection. Revised October 2009."},{"issue":"3 Suppl","key":"ref7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ygyno.2009.01.011","article-title":"Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses","volume":"115","author":"MP David","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.vaccine.2008.10.088","article-title":"Immunogenicity and tolerability of an HPV-16\/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15\u201355 years","volume":"27","author":"TF Schwarz","year":"2009","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"ref9","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1016\/j.vaccine.2008.01.013","article-title":"Age for HPV vaccination","volume":"26","author":"DM Harper","year":"2008","journal-title":"Vaccine"},{"issue":"3 Suppl 1","key":"ref10","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.ygyno.2008.06.029","article-title":"Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16\/18 infection and cervical disease in women 15\u201325 years of age","volume":"110","author":"DM Harper","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"1\u20132","key":"ref11","first-page":"72","article-title":"HPV vaccination catch up program\u2014utilisation by young Australian women","volume":"38","author":"E Weisberg","year":"2009","journal-title":"Aust Fam Physician"},{"issue":"8","key":"ref12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"EA Joura","year":"2015","journal-title":"The New England journal of medicine"},{"issue":"11","key":"ref13","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices","volume":"64","author":"E Petrosky","year":"2015","journal-title":"MMWR Morbidity and mortality weekly report"},{"issue":"50","key":"ref14","first-page":"7","article-title":"Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies","volume":"10","author":"DM Harper","year":"2010","journal-title":"Discov Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/1472-6963-12-123","article-title":"Estimation of the costs of cervical cancer screening, diagnosis and treatment in rural Shanxi Province, China: a micro-costing study","volume":"12","author":"JF Shi","year":"2012","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"ref16","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/ijc.25150","article-title":"Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China","volume":"127","author":"CE Levin","year":"2010","journal-title":"International journal of cancer"},{"issue":"Suppl 12","key":"ref17","doi-asserted-by":"crossref","first-page":"M17","DOI":"10.1016\/j.vaccine.2008.06.018","article-title":"Mathematical models of cervical cancer prevention in the Asia Pacific region","volume":"26","author":"SJ Goldie","year":"2008","journal-title":"Vaccine"},{"issue":"20","key":"ref18","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1056\/NEJMsa044278","article-title":"Cost-effectiveness of cervical-cancer screening in five developing countries","volume":"353","author":"SJ Goldie","year":"2005","journal-title":"The New England journal of medicine"},{"issue":"19","key":"ref19","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1093\/jnci\/94.19.1469","article-title":"Costs and benefits of different strategies to screen for cervical cancer in less-developed countries","volume":"94","author":"JS Mandelblatt","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1478-7547-4-13","article-title":"Estimating the cost of cervical cancer screening in five developing countries","volume":"4","author":"JD Goldhaber-Fiebert","year":"2006","journal-title":"Cost Eff Resour Alloc"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/ijc.21220","article-title":"Screening for cervical cancer in India: How much will it cost? A trial based analysis of the cost per case detected","volume":"117","author":"R Legood","year":"2005","journal-title":"International journal of cancer"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-3156.2010.02722.x","article-title":"Costs of cervical cancer screening and treatment using visual inspection with acetic acid (VIA) and cryotherapy in Ghana: the importance of scale","volume":"16","author":"W Quentin","year":"2011","journal-title":"Trop Med Int Health"},{"issue":"5","key":"ref23","doi-asserted-by":"crossref","first-page":"500 e1","DOI":"10.1016\/j.ajog.2008.03.064","article-title":"The economic burden of noncervical human papillomavirus disease in the United States","volume":"198","author":"D Hu","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"ref24","unstructured":"World Health Organization. World health report. Exceutive summary. Health of adults. WHO, 2016."},{"issue":"Suppl 5","key":"ref25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1469-0691.2012.03977.x","article-title":"Economic evaluation of vaccination: capturing the full benefits, with an application to human papillomavirus","volume":"18","author":"T Barnighausen","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"ref26","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2471\/BLT.06.038414","article-title":"Human papillomavirus and HPV vaccines: a review","volume":"85","author":"FT Cutts","year":"2007","journal-title":"Bull World Health Organ"},{"issue":"Suppl 3","key":"ref27","first-page":"S3\/35","article-title":"Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6\/11 disease","volume":"24","author":"CJ Lacey","year":"2006","journal-title":"Vaccine"},{"issue":"11","key":"ref28","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/ijc.26269","article-title":"Health and economic impact of HPV 16\/18 vaccination and cervical cancer screening in Eastern Africa","volume":"130","author":"NG Campos","year":"2012","journal-title":"International journal of cancer"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ygyno.2008.08.030","article-title":"Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa","volume":"112","author":"A Vijayaraghavan","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"11","key":"ref30","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2165\/00019053-200523110-00004","article-title":"Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature","volume":"23","author":"RP Insinga","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"ref31","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","article-title":"Methods for the evaluation of health care programmes","author":"Drummond","year":"2005"},{"key":"ref32","unstructured":"United Nations Environment Programme (UNEP)\/GRID. Topographic Maps: Southern Africa,topographic and political maps Geneva2005 [cited 2013 10\/02\/20013]. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.grida.no\/graphicslib\/detail\/southern-africa-topographic-and-political-map_1515\" xlink:type=\"simple\">http:\/\/www.grida.no\/graphicslib\/detail\/southern-africa-topographic-and-political-map_1515<\/ext-link>."},{"key":"ref33","unstructured":"Macmillan. Geography and map of Swaziland Matsapha 2005 [cited 2012 13\/12\/2012]. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/geography.about.com\/library\/cia\/blcswaziland.htm\" xlink:type=\"simple\">http:\/\/geography.about.com\/library\/cia\/blcswaziland.htm<\/ext-link>."},{"key":"ref34","unstructured":"Central Statistic office. Sawziland Population and Housing Census. Mbabane, Swaziland: Central Statistic office, 2007."},{"key":"ref35","unstructured":"Centers for Disease Control and Prevention. Centers for Disease Control and Prevention. CDC vaccine price list. Atlanta: 2015 14\/03\/2015. Report No."},{"key":"ref36","unstructured":"TrADING Economics. Swaziland GDP per Capita [Internet]. 2016 [cited 30\/03\/2017]. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.tradingeconomics.com\/swaziland\/gdp-per-capita\" xlink:type=\"simple\">http:\/\/www.tradingeconomics.com\/swaziland\/gdp-per-capita<\/ext-link>."},{"key":"ref37","unstructured":"The Joint United Nations Programme on HIV\/AIDS (UNAIDS). Swaziland country report on monitoring the political declaration on HIV and AIDS. Mbabane: NERCHA, 2012."},{"issue":"1","key":"ref38","doi-asserted-by":"crossref","first-page":"e0170189","DOI":"10.1371\/journal.pone.0170189","article-title":"Prevalence of and Associated Risk Factors for High Risk Human Papillomavirus among Sexually Active Women, Swaziland","volume":"12","author":"TG Ginindza","year":"2017","journal-title":"PloS one"},{"issue":"1","key":"ref39","first-page":"61","article-title":"The economic costs of illness: a replication and update","volume":"7","author":"DP Rice","year":"1985","journal-title":"Health care financing review"},{"issue":"9","key":"ref40","doi-asserted-by":"crossref","first-page":"e0139062","DOI":"10.1371\/journal.pone.0139062","article-title":"Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination","volume":"10","author":"E Ostensson","year":"2015","journal-title":"PloS one"},{"key":"ref41","unstructured":"The Clinic Group. Private Health Care Services Cost\/Pricing 2015. Mbabane, Swaziland."},{"key":"ref42","unstructured":"Hopelands Cancer Centre. Cervical Cancer Treatment Cost. Pietermaritzburg, South Africa 2016."},{"key":"ref43","unstructured":"The Kingdom of Swaziland. Cervical Cancer Screening Guidelines. Mbabane: Ministry of Health, 2013."},{"key":"ref44","unstructured":"The Kingdom of Swaziland. Annual National Sexual and Reproductive Health Programme Report. Ministry of Health, Monitoring and Evaluation Unit SID; 2015."},{"key":"ref45","unstructured":"The Kingdom of Swaziland. Health Management Information System (HMIS) Report. 2015."},{"key":"ref46","unstructured":"The Kingdom of Swaziland Gorvernment and UNFPA. Swaziland Population Projections 2007\u20132030, Central Statistics Office (CSO), editor. 2007."},{"key":"ref47","unstructured":"Phalala Fund Administration Office. Annual Report year 2014\/15. Mbabane,Swaziland: 2015."},{"issue":"7","key":"ref48","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/aogs.12143","article-title":"Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program","volume":"92","author":"E Ostensson","year":"2013","journal-title":"Acta obstetricia et gynecologica Scandinavica"},{"key":"ref49","unstructured":"The Kingdom of Swaziland. Swaziland National Cancer Registry. Report on Cases of cancers in Swaziland -2014-2015. Mbabane: Ministry of Health, 2016."},{"key":"ref50","article-title":"Guidelines for the management of sexually transmitted infections","year":"2003"},{"issue":"1","key":"ref51","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7314\/APJCP.2012.13.1.305","article-title":"Health and economic burden of HPV-related diseases in Singapore","volume":"13","author":"JJ Low","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"issue":"6 Suppl 1","key":"ref52","first-page":"S177","article-title":"Assessing the short-term and long-term burden of illness in cervical cancer","volume":"14","author":"RJ Lipsy","year":"2008","journal-title":"Am J Manag Care"},{"issue":"42","key":"ref53","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.1016\/j.vaccine.2012.07.056","article-title":"Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States","volume":"30","author":"HW Chesson","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"ref54","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3111\/13696990801961611","article-title":"Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium","volume":"11","author":"L Annemans","year":"2008","journal-title":"J Med Econ"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1471-2334-8-76","article-title":"Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study","volume":"8","author":"P Hillemanns","year":"2008","journal-title":"BMC Infect Dis"},{"issue":"32","key":"ref56","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.1016\/j.vaccine.2011.05.018","article-title":"Economic burden of HPV-related cancers in France","volume":"29","author":"I Borget","year":"2011","journal-title":"Vaccine"},{"issue":"11","key":"ref57","doi-asserted-by":"crossref","first-page":"e49699","DOI":"10.1371\/journal.pone.0049699","article-title":"Economic burden of human papillomavirus-related diseases in Italy","volume":"7","author":"G Baio","year":"2012","journal-title":"PloS one"},{"issue":"7","key":"ref58","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S2214-109X(14)70237-2","article-title":"Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study","volume":"2","author":"M Jit","year":"2014","journal-title":"The Lancet Global health"},{"issue":"5","key":"ref59","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","article-title":"Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis","volume":"15","author":"M Drolet","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"ref60","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1001\/jama.2014.95","article-title":"Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma","volume":"311","author":"E Herweijer","year":"2014","journal-title":"Jama"},{"issue":"12","key":"ref61","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/ijc.30035","article-title":"Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study","volume":"138","author":"E Herweijer","year":"2016","journal-title":"International journal of cancer"},{"key":"ref62","unstructured":"Centers for Disease Control and Prevention. CDC vaccine price list. [March 14, 2015]. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.cdc.gov\/vaccines\/programs\/vfc\/awardees\/vaccine-management\/price-list\/\" xlink:type=\"simple\">http:\/\/www.cdc.gov\/vaccines\/programs\/vfc\/awardees\/vaccine-management\/price-list\/<\/ext-link>."},{"issue":"6 Suppl 1","key":"ref63","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.ogx.0000221010.82943.8c","article-title":"Human papillomavirus: the burden of infection","volume":"61","author":"D Wiley","year":"2006","journal-title":"Obstetrical & gynecological survey"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S1473-3099(14)70841-2","article-title":"Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study","volume":"14","author":"Sepehr N Tabrizi","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"ref65","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3201\/eid2201.150736","article-title":"Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009\u20132013","volume":"22","author":"RL Cameron","year":"2016","journal-title":"Emerging Infectious Diseases"},{"key":"ref66","unstructured":"World Health Organisation. Evidence based recommendations on Human Papilloma Virus (HPV) Vaccines Schedules Background paper for SAGE discussions Geneva2014."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0177762","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T07:53:26Z","timestamp":1719215606000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0177762"}},"subtitle":[],"editor":[{"given":"Marcia Edilaine Lopes","family":"Consolaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,5,22]]},"references-count":66,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,5,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0177762","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,22]]}}}